Patient considerations in type 2 diabetes – role of combination dapagliflozin–metformin XR

References

• CDC Department of Health and Human Services [homepage on the Internet] National Diabetes Statistics Report 2014 [updated 2014; cited May 15, 2015]. Available from: http://www.cdc.gov/diabetes/pubs/statsreport14/national-diabetes-report-web.pdf Accessed September 3, 2015
   Google Scholar
• Menke A Casagrande S Geiss L Cowie CC Prevalence of and trends in diabetes among adults in the United States, 1988–2012 JAMA 2015 314 10 1021 1029 26348752
   PubMed Web of Science ®Google Scholar
• Stumvoll M Goldstein BJ van Haeften TW Pathogenesis of type 2 diabetes Endocr Res 2007 32 1–2 19 37 18271503
   PubMed Web of Science ®Google Scholar
• American Diabetes Association 4. Foundations of care: education, nutrition, physical activity, smoking cessation, psychosocial care, and immunization Diabetes Care 2015 38 Suppl 1 S20 S30 25537702
   PubMed Web of Science ®Google Scholar
• Handelsman Y Bloomgarden ZT Grunberger G American Association of Clinical Endocrinologists and American College of Endocrinology – clinical practice guidelines for developing a diabetes mellitus comprehensive care plan – 2015 Endocr Pract 2015 21 5 Suppl 1 1 87 25869408
   PubMed Web of Science ®Google Scholar
• Osterberg L Blaschke T Adherence to medication N Engl J Med 2005 353 5 487 497 16079372
   PubMed Web of Science ®Google Scholar
• Brown MT Bussell JK Medication adherence: WHO cares? Mayo Clin Proc 2011 86 4 304 314 21389250
   PubMed Web of Science ®Google Scholar
• American Diabetes Association Economic costs of diabetes in the U.S. in 2012 Diabetes Care 2013 36 1033 1046 23468086
   PubMed Web of Science ®Google Scholar
• Egede LE Gebregziabher M Dismuke CE Medication nonadherence in diabetes longitudinal effects on costs and potential cost savings from improvement Diabetes Care 2012 35 2533 2539 22912429
   PubMed Web of Science ®Google Scholar
• Cramer JA A systematic review of adherence with medications for diabetes Diabetes Care 2004 27 1218 1224 15111553
   PubMed Web of Science ®Google Scholar
• Inzucchi SE Bergenstal RM Buse JB Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes Diabetes Care 2015 38 1 1140 1149
   Web of Science ®Google Scholar
• Piette JD Heisler M Wagner TH Problems paying out-of-pocket medication costs among older adults with diabetes Diabetes Care 2004 27 2 384 391 14747218
   PubMed Web of Science ®Google Scholar
• Jha AK Aubert RE Yao J Teagarden JR Epstein RS Greater adherence to diabetes drugs is linked to less hospital use and could save nearly $5 billion annually Health Aff (Millwood) 2012 31 8 1836 1846 22869663
   PubMed Web of Science ®Google Scholar
• Benner JS Chapman RH Petrilla AA Tang SS Rosenberg N Schwartz JS Association between prescription burden and medication adherence in patients initiating antihypertensive and lipid-lowering therapy Am J Health Syst Pharm 2009 66 16 1471 1477 19667004
   PubMed Web of Science ®Google Scholar
• Bangalore S Kamalakkannan G Parkar S Messerli FH Fixed-dose combinations improve medication compliance: a meta-analysis Am J Med 2007 120 8 713 719 17679131
   PubMed Web of Science ®Google Scholar
• Balu S Simko RJ Quimbo RM Cziraky MJ Impact of fixed-dose and multi-pill combination dyslipidemia therapies on medication adherence and the economic burden of sub-optimal adherence Curr Med Res Opin 2009 25 11 2765 2775 19785511
   PubMed Web of Science ®Google Scholar
• Hussein MA Chapman RH Benner JS Does a single-pill antihypertensive/lipid-lowering regimen improve adherence in US managed care enrollees? A non-randomized, observational, retrospective study Am J Cardiovasc Drugs 2010 10 3 193 202 20387911
   PubMed Web of Science ®Google Scholar
• Cramer JA Benedict A Muszbek N Keskinaslan A Khan ZM The significance of compliance and persistence in the treatment of diabetes, hypertension and dyslipidaemia: a review Int J Clin Pract 2008 62 1 76 87 17983433
   PubMed Web of Science ®Google Scholar
• Jarab AS Almrayat R Alqudah S Predictors of non-adherence to pharmacotherapy in patients with type 2 diabetes Int J Clin Pharm 2014 36 4 725 733 24805800
   PubMed Web of Science ®Google Scholar
• Lopez JM Annunziata K Bailey RA Rupnow MF Morisky DE Impact of hypoglycemia on patients with type 2 diabetes mellitus and their quality of life, work productivity, and medication adherence Patient Prefer Adherence 2014 8 683 692 24855344
   PubMed Web of Science ®Google Scholar
• Grady S Fox KM Hardy E Association of weight loss and medication adherence among adults with type 2 diabetes mellitus: SHIELD (Study to Help Improve Early evaluation and management of risk factors Leading to Diabetes) Curr Ther Res Clin Exp 2013 75 77 82 24465048
   PubMedGoogle Scholar
• Kahn SE Cooper ME Del Prato S Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present and future Lancet 2014 383 9922 1068 1083 24315620
   PubMed Web of Science ®Google Scholar
• DeFronzo RA Pharmacologic therapy for type 2 diabetes mellitus Ann Intern Med 1999 131 281 303 10454950
   PubMed Web of Science ®Google Scholar
• DeFronzo RA Davidson JA Del Prato S The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia Diabetes Obes Metab 2012 14 1 5 14 21955459
   PubMed Web of Science ®Google Scholar
• Gerich JE Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications Diabet Med 2010 27 2 136 142 20546255
   PubMed Web of Science ®Google Scholar
• Cornell S Continual evolution of type 2 diabetes: an update on pathophysiology and emerging treatment options Ther Clin Risk Manag 2015 11 621 632 25931824
   PubMed Web of Science ®Google Scholar
• DeFronzo RA Goodman AM Efficacy of metformin in patients with non-insulin dependent diabetes mellitus N Engl J Med 1995 333 541 549 7623902
   PubMed Web of Science ®Google Scholar
• Bailey CJ Turner RC Metformin N Engl J Med 1996 334 9 574 579 8569826
   PubMed Web of Science ®Google Scholar
• Bloomgarden ZT Treatment of type 2 diabetes: the American Association of Clinical Endocrinologists Meeting, May 2002 Diabetes Care 2002 25 9 1644 1649 12196441
   PubMedGoogle Scholar
• American Diabetes Association Standards of medical care in diabetes – 2015 Diabetes Care 2015 38 1 S33 S37 S42 S46 25537705
   PubMed Web of Science ®Google Scholar
• Nathan DM Buse JB Davidson MB Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy Diabetes Care 2009 32 1 193 203 18945920
   PubMed Web of Science ®Google Scholar
• Kahn SE Haffner SN Heise MA Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy N Engl J Med 2006 355 2427 2443 17145742
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS) Group Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) Lancet 1998 352 9131 854 865 9742977
   PubMed Web of Science ®Google Scholar
• Blonde L San Juan ZT Fixed-dose combinations for treatment of type 2 diabetes mellitus Adv Ther 2012 29 1 1 13 22271157
   PubMed Web of Science ®Google Scholar
• Moulding T Dutt AK Reichman LB Fixed-dose combinations of antituberculous medications to prevent drug resistance Ann Intern Med 1995 122 951 954 7755232
   PubMed Web of Science ®Google Scholar
• Hutchins V Zhang B Fleurence RL Krishnarajah G Graham J A systematic review of adherence, treatment satisfaction and costs, in fixed-dose combination regimens in type 2 diabetes Curr Med Res Opin 2011 27 6 1157 1168 21466277
   PubMed Web of Science ®Google Scholar
• GLUCOVANCE^® (glyburide and metformin hydrochloride) [full prescribing information] Princeton NJ Bristol-Myers Squibb 2010 Available from: http://packageinserts.bms.com/pi/pi_glucovance.pdf Accessed July 21, 2015
   Google Scholar
• METAGLIP^® (glipizide and metformin hydrochloride) [full prescribing information] Princeton NJ Bristol-Myers Squibb 2009 Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021460s007lbl.pdf Accessed July 21, 2015
   Google Scholar
• PRANDIMET^® (repaglinide and metformin hydrochloride) [full prescribing information] Princeton, NJ Novo Nordisk 2010 Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022386s007lbl.pdf Accessed July 21, 2015
   Google Scholar
• JANUMET^® (sitagliptin and metformin hydrochloride) [full prescribing information] Whitehouse Station, NJ Merck and Co 2010 Available from: https://www.merck.com/product/usa/pi_circulars/j/janumet/janumet_pi.pdf Accessed July 21, 2015
   Google Scholar
• KOMBIGLYZE XR^® (saxagliptin and extended-release metformin hydrochloride) [full prescribing information] Princeton NJ Bristol-Myers Squibb 2010 Available from: http://www.azpicentral.com/kombiglyze-xr/pi_kombiglyze_xr.pdf#page=1 Accessed July 21, 2015
   Google Scholar
• ACTOPLUS MET^® (pioglitazone hydrochloride and metformin hydrochloride) and ACTOPLUS MET XR^® (pioglitazone hydrochloride and metformin hydrochloride extended-release) [full prescribing information] Deerfield, IL Takeda Pharmaceuticals America, Inc. 2010 Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021842s014s015lbl.pdf Accessed July 21, 2015
   Google Scholar
• AVANDAMET^® (rosiglitazone and metformin hydrochloride) [full prescribing information] Research Triangle Park NC GlaxoSmithKline 2008 Available from: https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Avandamet/pdf/AVANDAMET-PI-MG.PDF Accessed July 21, 2015
   Google Scholar
• AVANDARYL^® (rosiglitazone and glimepiride) [full prescribing information] Research Triangle Park NC GlaxoSmithKline 2009 Available from: https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Avandaryl/pdf/AVANDARYL-PI-MG.PDF Accessed July 21, 2015
   Google Scholar
• DUETACT^® (pioglitazone and glimepiride) [full prescribing information] Deerfield, IL Takeda Pharmaceuticals America 2010 Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021925s010s011lbl.pdf Accessed July 21, 2015
   Google Scholar
• INVOKAMET^® (canagliflozin and metformin hydrochloride) [full prescribing information] Titusville, NJ Janssen Pharmaceuticals 2014 Available from: http://www.invokanahcp.com/invokamet/prescribing-information.pdf Accessed July 22, 2015
   Google Scholar
• XIGDUO XR^® (dapagliflozin and metformin hydrochloride extended-release) [full prescribing information] Wilmington, DE AstraZeneca Pharmaceuticals 2014 Available from: http://www.azpicentral.com/xigduo/pi_xigduoxr.pdf Accessed July 22, 2015
   Google Scholar
• Bailey CJ Gross JL Peiters A Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomized, double-blind, placebo-controlled trial Lancet 2010 375 2223 2233 20609968
   PubMed Web of Science ®Google Scholar
• Bailey CJ Gross JL Hennicken D Dapagliflozin add on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102 week trial BMC Med 2013 11 43 23425012
   PubMed Web of Science ®Google Scholar
• Henry RR Murray AV Marmolejo MH Hennicken D Ptaszynska A List JF Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial Int J Clin Pract 2012 66 5 446 456 22413962
   PubMed Web of Science ®Google Scholar
• Nauck MA Del Prato S Meier JJ Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial Diabetes Care 2011 34 9 2015 2022 21816980
   PubMed Web of Science ®Google Scholar
• Matthaei S Bowering K Rohwedder K Grohl A Parikh S Study 05 Group Dapagliflozin improves glycemic control and reduces body weight as add-on therapy to metformin plus sulfonylurea: a 24-week randomized, double-blind clinical trial Diabetes Care 2015 38 365 372 25592197
   PubMed Web of Science ®Google Scholar
• Jabbour S Hardy E Sugg J Parikh S Study 10 Group Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study Diabetes Care 2014 37 3 740 750 24144654
   PubMed Web of Science ®Google Scholar
• Ferrannini E Ramos SJ Salsali A Tang W List JF Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial Diabetes Care 2010 33 10 2217 2224 20566676
   PubMed Web of Science ®Google Scholar
• Wilding JP Woo V Soler NG Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial Ann Intern Med 2012 156 6 405 415 22431673
   PubMed Web of Science ®Google Scholar
• Johnsson KM Ptaszynska A Schmitz B Sugg J Parikh SJ List JF Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin J Diabetes Complications 2013 27 479 484 23806570
   PubMed Web of Science ®Google Scholar
• Johnsson KM Ptaszynska A Schmitz B Sugg J Parikh SJ List JF Urinary tract infections in patients with diabetes treated with dapagliflozin J Diabetes Complications 2013 27 473 478 23849632
   PubMed Web of Science ®Google Scholar
• Parikh S Wilding J Jabbour S Hardy E Dapagliflozin in type 2 diabetes: effectiveness across the spectrum of disease and over time Int J Clin Pract 2015 69 2 186 198 25438821
   PubMed Web of Science ®Google Scholar
• Leiter LA Cefalu WT de Bruin TW Dapagliflozin added to usual care in individuals with type 2 diabetes mellitus with preexisting cardiovascular disease: a 24-week, multicenter, randomized, double-blind, placebo-controlled study with a 28-week extension J Am Geriatr Soc 2014 61 1252 1262 24890683
   PubMed Web of Science ®Google Scholar
• Dziuba J Alperin P Racketa J Modeling effects of SGLT-2 inhibitor dapagliflozin treatment versus standard diabetes therapy on cardiovascular and microvascular outcomes Diabetes Obes Metab 2014 16 628 635 24443793
   PubMed Web of Science ®Google Scholar
• Ptaszynska A Hardy E Johnnson E Parikh S List J Effects of dapagliflozin on cardiovascular risk factors Postgrad Med 2013 125 3 181 189 23748519
   PubMed Web of Science ®Google Scholar
• AstraZeneca Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events (DECLARE-TIMI58) Available from: https://clinicaltrials.gov/ct2/show/NCT01730534 Accessed January 21, 2016
   Google Scholar
• FDA FDA Drug Safety Communication: FDA Warns that SGLT2 Inhibitors for Diabetes May Result in a Serious Condition of Too Much Acid in the Blood [May 15, 2015]. Available from: http://www.fda.gov/Drugs/DrugSafety/ucm446845.htm Accessed August 15, 2015
   Google Scholar
• SGLT2 inhibitors PRAC makes recommendations to minimise risk of diabetic ketoacidosis European Medicines Agency Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/referrals/SGLT2_inhibitors/human_referral_prac_000052.jsp&mid=WC0b01ac05805c516f Accessed June 18, 2015
   Google Scholar
• FDA FDA Advisory Committee Meeting Regarding Dapagliflozin 5 mg and 10 mg Tablets Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM378076.pdf Accessed August 16, 2015
   Google Scholar
• Richy FF Sabido-Espin M Guedes S Corvino FA Gottwald-Hostalek U Incidence of lactic acidosis in patients with type 2 diabetes with and without renal impairment treated with metformin: a retrospective cohort study Diabetes Care 2014 37 8 2291 2295 24879835
   PubMed Web of Science ®Google Scholar
• Salpeter SR Greyber E Pasternak GA Salpeter EE Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus: systematic review and meta-analysis Arch Intern Med 2003 163 21 2594 2602 14638559
   PubMedGoogle Scholar
• Kasichayanula S Liu X LaCreta F Griffen SC Boulton DW Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2 Clin Pharmacokinet 2014 53 1 17 27 24105299
   PubMed Web of Science ®Google Scholar
• Kasichayanula S Liu X Pe Benito M The influence of kidney function on dapagliflozin exposure, metabolism and pharmacodynamics in healthy subjects and in patients with type 2 diabetes mellitus Br J Clin Pharmacol 2013 76 3 432 444 23210765
   PubMed Web of Science ®Google Scholar
• Kohan DE Fioretto P Tang W List JF Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control Kidney Int 2014 85 4 962 971 24067431
   PubMed Web of Science ®Google Scholar
• DeFronzo RA From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus Diabetes 2009 58 4 773 795 19336687
   PubMed Web of Science ®Google Scholar
• Blonde L Russell-Jones D The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1–5 studies Diabetes Obes Metab 2009 11 S3 26 34 19878259
   PubMed Web of Science ®Google Scholar
• Bailey CJ Renal glucose reabsorption inhibitors to treat diabetes Trends Pharmacol Sci 2011 32 2 63 71 21211857
   PubMed Web of Science ®Google Scholar